Every intervention Outliyr has scored for healthspan, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for healthspan; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
73 of 128 evaluated interventions score 3.0+ out of 10 for healthspan · 18 comparisons
Kodama 2009 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: Zone 2 touches cardiovascular capacity, metabolic control, mitochondrial function, mood, sleep, and cognitive aging. this verified…
Kumar 2023 anchors the most relevant signal. Glycine fits healthspan because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The score stays bounded because many…
Oosterveld 2009 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: Healthspan score reflects combined cardiovascular, pain, mood, sleep, stress, and heat-tolerance effects. this verified source summarizes…
Its four-minute high-intensity intervals raise VO2max, a top predictor of mortality, by about 7 % in controlled trials Helgerud 2007. VO2max remains one of the strongest healthspan markers available in clinical exercise…
Red Light Therapy has useful signals across skin, hair, pain, recovery, eyes, oral tissue, and mood rather than one narrow pathway. Boyer 2024 adds age-related macular degeneration evidence, and Wunsch 2014 supports…
Sauna touches several aging-relevant systems at once: cardiovascular mortality, neurocognitive disease, hypertension, and systemic inflammation. Laukkanen 2018, the Mayo Clinic Proceedings review, frames sauna as a multi-system practice that reduces the risk…
Harrison 2009 anchors the most relevant signal. Rapamycin fits healthspan when mTORC1 modulation, autophagy, immune aging, or senescence biology is the actual target. The score stays bounded because human longevity endpoints remain…
Perkovic 2024 reported 24% lower major kidney disease or death composite risk in type 2 diabetes plus CKD. Healthspan improves most when a person carries obesity, diabetes, CVD, CKD, HFpEF, or MASH…
Dhillon 2024 reports 25-article systematic review; mixed preliminary clinical evidence, heterogeneity, and need for stronger trials. Zhou 2024 points in the same direction, but route, dose, baseline status, and outcome tracking decide…
Filip 2007 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: this verified source reported lower frailty scores in aged mice. This is the cleanest healthspan signal,…
Healthspan value comes from durable skill acquisition: focus, arousal regulation, sleep stability, and post-TBI recovery support daily function. Van Doren 2019 is important because maintained gains imply more than a transient session…
Eisenberg 2016 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: Broad autophagy effects support healthspan, but the human outcomes remain mostly dietary observational plus…
Whole-Body Vibration also shows potential anti-inflammatory effects, though the direction varies by endpoint, as noted in a recent meta-analysis of preclinical and clinical studies Wang 2024. Evidence for sarcopenia improvement remains inconsistent,…
Guan et al. 2024 supports the core mechanism. Xu 2018 found D+Q improved physical function and post-treatment survival in old mice; human healthspan outcomes remain unproven. The score stays bounded because Senolytics…
SIT efficiently raises VO2max, one of the strongest predictors of mortality available. Mandsager 2018 found elite cardiorespiratory fitness associated with about 80 percent lower all-cause mortality versus low fitness across 122,007 adults,…
Tirzepatide reduces body weight, waist circumference, and blood pressure in overweight or obese people without diabetes, outcomes that correlate with longer functional years Liu et al. 2024. Tirzepatide also improves heart-failure with…
Healthspan support comes from injury recovery, corneal repair, cardiac preclinical work, and neurological models. Di 2026 reviews kidney-repair mechanisms, but it is narrative and translational, not proof of broad human healthspan benefit.…
The same food pattern that lowers cardiovascular and metabolic risk also tracks with preserved cognition and function in later life. Shishtar 2020 in the Framingham Offspring Cohort linked the highest flavonoid intake…
Hagiyama 2024 reports 12 RCTs; 622 patients; low-certainty improvement in patient-reported outcomes and very-low-certainty strength signal after lower-limb surgeries. Wittholz 2024 points in the same direction, but route, dose, baseline status, and…
Wu 2025 anchors the most relevant signal. Thymosin Alpha-1 fits healthspan when immune modulation is medically relevant and monitored rather than casually guessed. The score stays bounded because the best evidence is…
Zhang et al. 2024 supports limited benefit. Higher HRV and lower chronic inflammation align with functional aging, but VNS has no direct human healthspan trial evidence. The score stays bounded because Vagus…
The evidence for Metformin's healthspan benefit is strongest in people with diabetes or high-risk prediabetes, where preventing hyperglycemia-related complications directly lengthens functional years. Observational links to lower cancer incidence and increased longevity…
The existing rationale points to this narrower claim: Healthspan earns a modest positive score because energy, cognition, and redox resilience matter for functional aging. The clinical evidence is not healthspan-specific. That does…
Multiple healthspan pathways: cardiovascular, cognitive, sleep, inflammation. Higher HRV is itself a solid longevity biomarker. The score stays bounded because HRV Biofeedback evidence for healthspan can depend on breathing cadence, adherence, baseline…
Kreider 2017 reports Foundational 87-citation position stand; safe up to 30 g/day for 5 years. Lanhers 2015 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether…
The healthspan score remains a mechanism-weighted 6. Pickart 2018 summarizes protective gene data across repair and inflammation pathways, but the audit found no recent human RCT or meta-analysis that upgrades systemic healthspan…
Rucking trains three things that decline with age at once: aerobic capacity, the ability to carry load, and lower-body function. It inherits walking's strong mortality association (Paluch 2022) and adds a loading…
Ergothioneine touches several aging-related systems at once without a clear downside. The same blood-level associations that support cardiovascular and cognitive cases also link low ergothioneine to frailty in Kondoh 2022, which found…
Protein adequacy supports function with aging, although the grass-fed label itself adds little. The strongest support comes from Shimomura Y. et al. 2006, but the practical rating stays bounded by study size,…
Muscle preservation, strength maintenance, and low-load accessibility make BFR relevant to aging health, especially where conventional resistance training is not tolerated. The score stays bounded because Blood-Flow Restriction Training evidence for healthspan…
Liu 2024 reports 11 RCTs; 346 healthy participants; significant improvements reported across fatigue, cognition, and exercise-efficiency endpoints overall; endpoint details are limited. Maleki-Hajiagha 2024 points in the same direction, but route, dose,…
The evidence points to a plausible use case without proving a universal response. Al-dulaimi et al. 2025 is the best anchor here because it reports independent in vitro study and normal epithelial…
The functional gains in strength, gait, glycemic control, and inflammation are exactly the kind of compression-of-morbidity signals healthspan is about, per Kumar 2023. The discount is that all of it is single-lab…
Zhang 2024 anchors the most relevant signal. NMN fits healthspan when raising NAD+ is likely to matter for older, metabolically stressed, or performance-tracking users. The score stays bounded because NAD+ rises more…
Tesamorelin improves VAT, liver fat, and selected metabolic markers in high-risk groups, which may support healthspan. The score stays capped because GH/IGF-1 signaling has complex aging biology and no lifespan or hard…
Lincoff 2023 reports TRAVERSE cardiovascular outcomes trial in 5,246 hypogonadal men with cardiovascular risk; major cardiovascular events non-inferior, with monitoring-relevant safety signals. Cruickshank 2024 points in the same direction, but route, dose,…
Cognitive aging and telomere or senescence findings justify a small positive healthspan signal. Hachmo 2020 supports immunosenescence reduction in older adults. Hadanny 2020 supports cognitive gains in the same population. Clinical healthspan…
The case rests on vitamin C being essential for collagen, immune competence, iron handling, and antioxidant defense, all of which degrade visibly in deficiency and recover with repletion. Adequate status plausibly supports…
Pandit 2016 anchors the most relevant signal. Shilajit fits healthspan when purified resin is matched to hormones, sperm parameters, strength fatigue, bone markers, or energy tracking. The score stays bounded because most…
Muscle mass and strength are central healthspan variables, and WB-EMS can preserve or improve them when conventional training is inaccessible. The score stays moderate because long-term hard outcomes and post-cessation durability remain…
Mitochondrial quality control is a credible healthspan target, but human functional endpoints remain early. The healthspan score reflects mechanism plus small trials, not proven aging modification. That makes Urolithin A more defensible…
Martens 2018 supports direction more than certainty. The existing rationale points to this narrower claim: Multi-system NAD+ support and disease-population signals justify interest, but healthy-adult function remains mixed per this verified source.…
The evidence points to a plausible use case without proving a universal response. Ehlers JP et al. 2024 is the best anchor here because it reports 176 participants randomized and missed primary…
Chang 2024 reports Verified audit Track 1 and Track 2 source; supports narrow intradiscal lumbar disc efficacy, especially versus steroid injection at 6 months and similar outcome to microdiscectomy at 18 months.…
SLU-PP-332 targets mitochondrial and metabolic pathways that overlap with those activated by aerobic training, which are linked to longer functional lifespan in animal models. A follow-up mouse study reported enhanced oxidative capacity…
Healthspan potential comes from multi-system coverage across cognition, mood, gut, immune, and nerve support. Human data remain too thin to treat Lion's Mane as a broad healthy-aging staple.
The cluster of blood-pressure, lipid, and glucose improvements supports a modest healthspan case, but it rests on surrogate markers rather than functional aging endpoints.
The KiSel-10 cardiovascular mortality result and the benign safety profile make CoQ10 healthspan-relevant for older, at-risk adults, but it is not a broad healthspan intervention with direct endpoint data outside cardiovascular outcomes.
Healthspan support is plausible through mood, sleep, and vision preservation, but the clinical evidence is endpoint-specific and does not prove broad aging benefits.
Healthspan support is modest and context-dependent. Omega-3 can help inflammation, triglycerides, and mood in the right user, but does not act like a broad geroprotector.
Healthspan support is indirect through stress, libido, mood, and androgen tone in older men. Evidence does not reach the standard of exercise, sleep, creatine, or cardiometabolic interventions.
Healthspan-relevant signals come from D plus Q pilots in IPF (Justice 2019) and diabetic kidney disease (Hickson 2019), plus the BP and uric acid effects of quercetin alone. Physical function improved in…
Late-life dosing improved brain and kidney aging markers in senescence-accelerated mice, a cross-organ healthspan signal (Kepchia et al. 2021). It is stronger than most marketed longevity compounds, yet entirely preclinical.
Metabolic disease improvement could extend healthspan in high-risk obesity, but retatrutide has no long-term morbidity, mortality, cancer, dementia, or frailty outcomes. Authority gaps keep this from becoming a broad healthspan recommendation.
Hydration and mineral balance support multiple aging-related systems, especially in older adults with reduced thirst, but the effect is foundational rather than therapeutic.
Broad tissue-protective effects support healthy aging in theory. No human healthspan trial exists, so this score reflects repair relevance in aging populations, not longevity proof.
Collagen peptides may support healthspan indirectly through mobility, skin structure, glycine intake, and training tolerance. This cumulative case is reasonable but not disease-prevention evidence.
Healthspan inherits the longevity gap. The anti-fibrotic, anti-inflammatory, and pro-angiogenic profile is consistent with healthspan-extending interventions, but no human aging or healthspan endpoint has been measured.
Cognitive aging is a core healthspan domain, and PS has targeted evidence in older adults with memory complaints. The rating stays moderate because guideline bodies remain cautious.
Cognitive preservation and stroke-recovery mechanisms are healthspan-relevant, especially in older adults, but the human evidence remains geographically narrow.
Healthspan benefit is extrapolated from metabolic disease improvement, not directly proven. The case is reasonable for insulin-resistant adults and weak for already healthy users.
MOTS-c touches healthspan-relevant pathways including metabolic health, exercise capacity, inflammation, and muscle homeostasis. Miller 2022 reviews MDP healthspan biology, but clinical translation remains early.
Plausible via the Okinawan dietary association and immune and anti-inflammatory mechanisms, but no direct healthspan trials.
As with longevity, the broad nutrient profile and gentle cardiometabolic nudges are plausibly healthspan-supportive, but no direct healthspan endpoint has been measured in chlorella trials.
Plausible via antioxidant and anti-aging animal signals, but no human healthspan evidence.
Plausible via immune and anti-inflammatory pathways, anchored by reishi's adjunct-cancer QoL signal, but no direct healthspan trial.
Sarcopenia, kidney and metabolic findings are healthspan-adjacent, but all are single-organ animal endpoints rather than a demonstrated healthspan outcome (Dantas et al. 2022).
Indirect at best, via inflammation and metabolic markers. No direct healthspan outcomes in humans.
Indirect via stress and sleep optimization; no direct healthspan trials.
HA supports tissues that decline with age, and dietary or supplemental HA is benign, but there is no longevity or healthspan outcome data; the score reflects plausible support, not demonstrated benefit.
Mineral adequacy supports general health, but there is no direct healthspan trial of marine plasma.
Plausible healthspan gains via better metabolic markers, but unproven as a direct endpoint for orforglipron.
Nothing matches those filters.
Monthly out-of-pocket cost at the most accessible legitimate channel, at the dose the score was given for. 24 of 73 are not priced yet; those cells are left blank rather than guessed.
| Intervention | Monthly cost | At dose | How you get it |
|---|---|---|---|
| Zone 2 Cardio | Not priced yet | Over the counter | |
| Glycine | $2–$3 | 3 g oral glycine | Over the counter |
| Infrared Sauna | $36–$73 | 55-60 degrees C, 20-30 min | Over the counter |
| Norwegian 4×4 | Not priced yet | Over the counter | |
| Red Light Therapy | $17–$43 | 10-20 min at 6-12 inches, full chest/face/back rotation | Over the counter |
| Traditional Sauna (Finnish Dry-Heat) | $50 | 15 to 20 minutes at 80 to 100 C | Over the counter |
| Rapamycin | $15–$50 | 3 mg | Prescription |
| Semaglutide | $199–$349 | 0.25 mg weeks 1 to 4, 0.5 mg weeks 5 to 8, 1.0 mg weeks 9 to 12, 1.7 mg weeks 13 to 16, 2.4 mg week 17 onward | Prescription |
| Molecular Hydrogen | Not priced yet | ||
| Ca-AKG (Calcium Alpha-Ketoglutarate) | $15–$30 | 1 g/day generic Ca-AKG oral | Over the counter |
| Neurofeedback | Not priced yet | ||
| Spermidine | $40–$90 | 1-3 mg/day oral WGE | Over the counter |
| Whole-Body Vibration | $50–$100 | 30 Hz, roughly 0.3g, 10-20 min standing | Over the counter |
| Senolytics | Not priced yet | ||
| Sprinting (Sprint Interval Training) | Not priced yet | ||
| Tirzepatide | $299–$449 | 2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg | Prescription |
| TB-500 (Thymosin Beta-4 Fragment) | Not priced yet | ||
| Polyphenols (Dietary) | Not priced yet | ||
| Essential Amino Acids | Not priced yet | ||
| Thymosin Alpha-1 | $100–$400 | 1.6 mg subcutaneous | Prescription |
| Vagus Nerve Stimulation | $4–$8 | 10-20 min auricular tVNS at comfortable perceptible intensity | Over the counter |
| Metformin | $4–$30 | 500 mg with dinner for 1 week, then 500 mg twice daily for 1 week, then increase by 500 mg/week toward 1000 mg twice daily as tolerated | Prescription |
| Methylene Blue | $13–$40 | 0.5-5 mg oral | Over the counter |
| HRV Biofeedback | $5 | 20 min/session at individual RF (4.5 to 6.5 bpm) | Over the counter |
| Creatine Monohydrate | Not priced yet | ||
| GHK-Cu | $30–$100 | 0.5-3% topical serum or cream | Over the counter |
| Rucking (Weighted Walking) | Not priced yet | ||
| Ergothioneine | Not priced yet | ||
| Grass-Fed Whey Protein | $40–$80 | 20-40 g protein | Over the counter |
| Blood-Flow Restriction Training | Not priced yet | ||
| Astaxanthin | Not priced yet | ||
| Epitalon | $95–$1,100 | 5-10 mg/day subcutaneous | Grey market |
| GlyNAC (Glycine + N-Acetylcysteine) | $10–$30 | Glycine and NAC at ~100 mg/kg/day each | Over the counter |
| NMN (Nicotinamide Mononucleotide) | $40–$100 | 500 mg/day oral | Over the counter |
| Tesamorelin | $250–$500 | 2 mg subcutaneous daily in the evening | Prescription |
| TRT (Testosterone Replacement Therapy) | $50–$300 | Clinician-selected formulation at the lowest dose likely to restore physiologic testosterone | Prescription |
| Hyperbaric Oxygen Therapy | $3,000–$6,000 | 2.0 ATA for 90 minutes with air breaks | In clinic |
| Vitamin C (Ascorbic Acid) | Not priced yet | ||
| Shilajit | $25–$50 | 500 mg purified shilajit | Over the counter |
| Full-Body EMS | Not priced yet | ||
| Urolithin A | $50–$100 | 500 mg/day | Over the counter |
| NR (Nicotinamide Riboside) | $40–$50 | 250-300 mg/day oral | Over the counter |
| SS-31 (Elamipretide) | $200–$500 | 5-10 mg/day subcutaneous | Grey market |
| Ozone Therapy | $520–$2,600 | 20-30 mcg/mL ozone, roughly 1,000-1,500 mcg total per session | In clinic |
| SLU-PP-332 | $30–$80 | 3-5 mg/day oral | Research use only |
| Lion’s Mane | $20–$40 | 3 g/day fruiting body extract | Over the counter |
| Spirulina | $10–$25 | 1 to 4.5 g/day | Over the counter |
| Coenzyme Q10 (CoQ10 / Ubiquinol) | $15–$40 | 100-200 mg/day | Over the counter |
| Saffron | Not priced yet | ||
| Omega-3 | $20–$40 | 1-2 g/day combined EPA+DHA | Over the counter |
| Tongkat Ali | $20–$40 | 200 mg/day Physta standardized extract | Over the counter |
| Quercetin | $20–$50 | 200 mg/day | Over the counter |
| J-147 | Not priced yet | ||
| Retatrutide | $130–$960 | 2 mg, then 4 mg, then 8 mg or 12 mg weekly depending on protocol and tolerability | Research use only |
| Electrolytes | Not priced yet | ||
| BPC-157 | $40–$80 | 250 to 500 mcg SC 1 to 2x/day near injury site | Grey market |
| Collagen Peptides | $8–$40 | 2.5-10 g hydrolyzed collagen peptides | Over the counter |
| Thymosin Beta-4 (Tβ4) | Not priced yet | ||
| Phosphatidylserine | $20–$50 | 300 mg/day total, split as 100 mg three times daily or 300 mg once daily with food | Over the counter |
| Semax | $12–$60 | 300-600 mcg/day of 0.1% spray | Grey market |
| Berberine | $15–$25 | 500 mg berberine HCl three times daily with meals | Over the counter |
| MOTS-c | $100–$200 | 5-10 mg SC | Research use only |
| Fucoidan (Brown Seaweed Polysaccharide) | Not priced yet | ||
| Chlorella | $10–$50 | 5-10 g/day | Over the counter |
| Glutathione (GSH) | $20–$45 | 1,000 mg/day | Over the counter |
| Pine Pollen | $20–$45 | 5 to 10 g powder per day | Over the counter |
| Adaptogenic Mushrooms (Reishi, Cordyceps, Chaga) | $15–$40 | 1.5 to 1.8 g/day standardized extract | Over the counter |
| BAM15 | Not priced yet | ||
| Curcumin | $15–$40 | 500 mg curcuminoids | Over the counter |
| L-Theanine | $3–$8 | 200 mg L-theanine + 100 mg caffeine | Over the counter |
| Hyaluronic Acid | Not priced yet | ||
| Quinton Marine Plasma (Seawater Minerals) | Not priced yet | ||
| Orforglipron (Foundayo) | $149–$299 | Start low, step up to 36 mg | Prescription |
Head-to-head reports and category rankings that name a winner on this use case.
This page ranks by the live endurance-cardio subrating, not by BioHarmony overall, and the order flips. SLU-PP-332 leads at 6.5–7.0/10 despite carrying the lowest overall score on the…
This page ranks by the live Body Composition subrating, fat loss and body composition, not the overall BioHarmony score. Tesamorelin leads at 7.5–8.0/10, and it also carries the…
Neither, if fat loss is the goal. Both score 2.0–2.5/10 on body composition, which is the row a vendor sells them on. AOD-9604 scores 3.0–3.5/10 overall and its…
BPC-157 for structural repair, KPV for inflammation you cannot afford to stimulate. BPC-157 scores gut health 9.0–9.5/10 against KPV's 7.0–7.5/10 and wins nearly every other row, because it…
Cerebrolysin scores 6.0–6.5/10 and P-21 scores 5.0–5.5/10, and the gap is entirely about human data. Cerebrolysin has thousands of trial participants, contested by two independent Cochrane reviews. P-21…
CoQ10 scores 7.0–7.5/10 and methylene blue 6.0–6.5/10, yet methylene blue wins eleven of the seventeen shared use cases. The overall gap is risk, not effect. Methylene blue inhibits…
Neither, yet. Both have zero human trials, zero human pharmacokinetics and research-only access. PE-22-28 scores 4.5–5.0/10 and dihexa 4.0–4.5/10, and the gap is entirely safety: dihexa potentiates the…
On weight loss they tie, and neither is a drug you can legitimately buy. Both score 7.5/10 for body composition, and both are investigational Lilly molecules with phase…
Epitalon, if sleep is the question. It scores sleep quality 6.5–7.0/10 against pinealon's 1.5–2.0/10, because it acts on the pineal gland and melatonin output while pinealon is a…
Thymulin scores 6.5–7.0/10, thymalin 5.5–6.0/10, and they are not interchangeable. Thymulin is a defined zinc-dependent peptide with receptor-level science, stronger inflammation data and a much cheaper course. Thymalin…
HBOT scores 5.5–6.0/10 and ozone 5.0–5.5/10, but ozone wins several use cases outright. Pick HBOT for wounds, cognition and neuro recovery, at $3,000 to $6,000 a month. Pick…
Metformin scores 6.5–7.0/10 and rapamycin 6.5–7.0/10, which settles nothing. Rapamycin owns the aging-biology rows: longevity 8.0/10, autophagy 8.5/10, senescence 7.8/10, plus replicated mouse lifespan data. Metformin owns everyday…
Zone 2 Cardio, at 8.0–8.5 out of 10 for healthspan. Kodama 2009 makes the claim plausible but incomplete.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 7.5–8.0 out of 10 for healthspan.
73 of the 128 interventions evaluated for healthspan score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
